Poly MVA,the abbreviation MVA symbolizes Minerals, Vitamins, and Amino acids.
Poly MVA is a proprietary formulation that holds the following:
- Alpha-lipoic acid
Its chief energetic constituent is a lipoic acid/palladium composite, that is retailed as a nutritional supplement and is being claimed as synthetic reductase by the pharmaceutical companies.
Specific biochemical interaction:
Poly MVA chosen specific biochemical interactions are directly associated with its constitutional composition. It comprises a permanently attached polymer of lipoic acid and palladium with a thiamine interior. This multiplex is a liquid crystal polymer instead of a single molecule, which permits it to present a unified oxidation and reduction result more resourcefully. As soon as glucose goes into a cell, it is shattered down into pyruvate (when there is lack of oxygen.) Consequently the latter goes into the mitochondria and is swiftly oxidized to acetyl-coenzyme A.
During that respiration (which uses oxygen) acetyl-CoA is subsequently directed into the Krebs/citric acid cycle to generate the condensed type of Nicotinamide Adenine Dinucleotide (NADH). The latter contributes its electron to the electron transport series in order to compel the phosphorylation of Adenosine Triphosphate (ATP). The power requirements of the body are granted by separating ATP into Adenosine Diphosphate as well as a liberated phosphate molecule. LAPd was fashioned to shove the electron power from itself to DNA and therefore substitute the electrons mislaid in normal cells (due to the oxidative harm associated with emission and chemotherapy.)
LAPd has been investigated for its efficacy in arresting the development of glioblastoma cells in a living organism.
Research investigations have established that LAPd supplies electrons to DNA by means of mitochondria. This transport of electrons offers an extra source of power to typical cells. On the other hand, malignant cells are metabolically opposed and operate in a hypoxic milieu. Given that surplus electrons have a smaller amount of oxygen to allow them in the malignant cell, an indigenous creation of free radicals happens at the mitochondrial membrane. This stimulates apoptosis by easing the discharge of cytochrome C from the internal mitochondrial membrane, permitting the creation of a programmed cell demise multiplex in the cytoplasm. This composite causes stimulation of the caspase outpouring of enzymes that annihilate the malignant cells. Since healthy cells are richly oxygenated, LAPd is nontoxic to them, and they actually benefit from the energy boost.
Latest facts have concentrated on the chore of Poly-MVA and the possibility of a malignant cell to physiologically become accustomed to an atmosphere where there is not sufficient supply of oxygen.
These physiological transformations are effectuated by a molecule known as hypoxia inducible factor-1 (HIF-1.) The latter intensifies in hypoxic circumstances to endorse an augmentation in vascular endothelial growth factor (VEGF, an advocate of the development of new blood vessels); glucose transport 1 (GLUT1); glycolytic enzymes. The latter are the decisive integrants in anaerobic respiration. Erythropoietin (EPO)
accountable for the segregation of red blood cells).4 Poly-MVA seems to reduce the manufacture of HIF-1, thereby limiting the capability of the cell to become accustomed to its milieu and afterwards cause it to become more susceptible to apoptotic cell demise.
Case study of a patient suffering from Multiple Myeloma:
Preceding the spring of the year 2006, KW began experiencing fatigue and desired to snooze all through the day. Though he had continued the intake of thalidomide, yet had continued the thalidomide, yet he had ceased the intake of Poly MVA repeatedly once more and took it occasionally. His RBC sum became tremendously depressed, and he needed more than a few blood transfusions during the spring of the year 2006. His doctor prescribed Revimid to which he experienced a nasty response; therefore, he had to be hospitalized for three days during the month of August in the year 2006. He had entirely ceased the intake of Poly MVA. He failed to recapture his brain operation and also experienced some alteration in persona and became irritable. Afterwards, he was swapped to a pain-alleviation patch. He began waning swiftly and died on the 9th of November 2006. By pursuing a consolidative preparation of remedy, he was able to surpass the three month disposition that his oncologist had predicted.
Another case study:
JS was detected to be suffering from an aggressive glioblastoma stage 4 in December of the year 2003 at the age of 48. He underwent surgery during which all noticeable brain tumor was detached. He also endured 33 rounds of intensity modulated radiation therapy as well as rotating gamma.
He commenced taking Poly MVA in January 2004 and his PET scan done during September 2004 was found to be entirely unambiguous.
Exploratory surgery was carried out on October 2004; according to the pathology report, there was no evidence of any malignancy.
JS continues to be on a maintenance dose of two teaspoons of Poly-MVA every day and the MRI findings are very encouraging.
One more case study:
FA was detected with stage 4, non-small cell lung malignancy at sixty-one years of age and taxol and carboplatin were administered to her from July 2004 until the termination of the year September 2004. Throughout this time, she endured two attacks of Myocardial Infarction. Given that her heart was distressed by chemotherapy, she was unable to put up with chemotherapeutic drugs.
In October, she began taking Poly MVA , five months afterward, the CT scan of her chest did not reveal any tumor. In December, she reduced her dose of Poly-MVA to one teaspoon every day. In addition, she started using 100 mg of CoQ10 and four capsules of fish oil every day. Currently, not only she is doing well but continues in remission.
These aforementioned case studies reveal a remarkable reaction to treatment with Poly MVA, after conservative medication was administered for mitigative management or in an effort to reduce the development of sickness. Not any of these patients was likely to attain clinical reduction or long-standing established sickness.
By and large, NSCLC and glioblastoma are detected at stage 4, decreasing the possibility that conservative management will attain any significant gain. Even though, some of these intrusions may decelerate the development of sickness or improve continued existence free of sickness, the fundamental point is that not any of the conservative remedies utilized in the management of these cases lengthen general endurance for these lethal varieties of malignancy. As yet, a lot of queries (regarding Poly-MVA) are unresolved and consist of the following:
- The most favorable dose?
- Is the most favorable dose decided by :
The sort of malignancy
The genetics of the patient
Environment of the patient
- The duration for which a patient should continue on the most favorable /remedial prescribed amount?
- At what time should a patient think about reducing the dosage?
(In the case of KW, reducing the dosage had terrible sequels )
- In which kind of malignancy or remedies should the utilization of Poly-MVA be taken into account so as to attain most favorable results?
- If conservative therapy is unsuccessful on a patient, should Poly-MVA be used unaccompanied or as an adjunct to additional conservative therapy?
- Can the single-handed utilization of Poly-MVA or its use as an adjunct to additional traditionalist therapy be determined to upgrade the results?
- What sorts of malignancy are austerely expected to act in response to Poly-MVA?
The objective of the continuing gathering of medical records is to respond to these and additional urgent queries. While additional medical records are being stockpiled, expectantly the way for a significant extensive research will be overlaid.